| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7842687 | TEVA PHARMS INTL | Cephalotaxane derivatives and their processes of preparation and purification |
Mar, 2019
(5 years ago) | |
| USRE45128 | TEVA PHARMS INTL | Cephalotaxane derivatives and their processes of preparation and purification |
Mar, 2019
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6987103 | TEVA PHARMS INTL | Treatment of chronic myelogenous leukmia, resistant or intolerant to ST1571, involving homoharringtonine alone or combined with other agents |
Oct, 2026
(2 years from now) | |
Synribo is owned by Teva Pharms Intl.
Synribo contains Omacetaxine Mepesuccinate.
Synribo has a total of 3 drug patents out of which 2 drug patents have expired.
Expired drug patents of Synribo are:
- US7842687
- USRE45128
Synribo was authorised for market use on 26 October, 2012.
Synribo is available in powder;subcutaneous dosage forms.
Synribo can be used as treatment of patients with leukemia including chronic myeloid/myelogenous leukemia (cml), treatment of leukemia, treatment of patients with tyrosine kinase inhibitor (tki) resistant or intolerant chronic myeloid/myelogenous leukemia (cml).
Drug patent challenges can be filed against Synribo from 26 October, 2016.
The generics of Synribo are possible to be released after 26 October, 2026.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-32) | Oct 26, 2019 |
| New Chemical Entity Exclusivity(NCE) | Oct 26, 2017 |
| Orphan Drug Exclusivity(ODE) | Oct 26, 2019 |
Drugs and Companies using OMACETAXINE MEPESUCCINATE ingredient
NCE-1 date: 26 October, 2016
Market Authorisation Date: 26 October, 2012
Treatment: Treatment of patients with tyrosine kinase inhibitor (tki) resistant or intolerant chronic myeloid/myelogenous leukemia (cml); Treatment of patients with leukemia including chronic myeloid/myelogenous...
Dosage: POWDER;SUBCUTANEOUS
SYNRIBO family patents
